AI Verdict
KALV has stronger fundamentals based on our AI analysis.
KARX vs KALV Fundamental Comparison
| Metric | KARX | KALV |
|---|---|---|
| Revenue | $56.5M | $13.7M |
| Net Income | $-4.0M | $-158.9M |
| Net Margin | -7.2% | -1,160.0% |
| ROE | N/A | -934.8% |
| ROA | -21.9% | -46.7% |
| Current Ratio | 1.15x | 7.22x |
| Debt/Equity | N/A | 0.31x |
| EPS | $-0.05 | $-2.97 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KARX vs KALV: Frequently Asked Questions
Is KARX or KALV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KALV has stronger fundamentals. KARX is rated STRONG SELL (97% confidence) while KALV is rated HOLD (45% confidence). This is not investment advice.
How does KARX compare to KALV fundamentally?
Karbon-X Corp. has ROE of N/A vs KalVista Pharmaceuticals, Inc.'s -934.8%. Net margins are -7.2% vs -1,160.0% respectively.
Which stock pays higher dividends, KARX or KALV?
KARX has a dividend yield of N/A or no dividend while KALV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KARX or KALV for long term?
For long-term investing, consider that KARX has STRONG SELL rating with 97% confidence, while KALV has HOLD rating with 45% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KARX vs KALV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KARX vs KALV, the AI consensus favors KALV based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.